{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T06:29:34Z","timestamp":1780554574219,"version":"3.54.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T00:00:00Z","timestamp":1674691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1171111"],"award-info":[{"award-number":["OPP1171111"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.vaccine.2023.01.048","type":"journal-article","created":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T15:02:20Z","timestamp":1675522940000},"page":"1657-1667","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Safety, tolerability, and immunogenicity of inactivated poliovirus vaccine with or without E.coli double mutant heat-labile toxin (dmLT) adjuvant in healthy adults; a phase 1 randomized study"],"prefix":"10.1016","volume":"41","author":[{"given":"Rahsan","family":"Erdem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilse","family":"De Coster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanchanamala","family":"Withanage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laina D.","family":"Mercer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Marchant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Taton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Cools","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Lion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Cassels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Ivinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Locke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kutub","family":"Mahmood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter F.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Gast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica A.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret E.","family":"Ackerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Konopka-Anstadt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo A.","family":"Mainou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Van Damme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.vaccine.2023.01.048_b0005","doi-asserted-by":"crossref","first-page":"784","DOI":"10.15585\/mmwr.mm6925a4","article-title":"Progress toward polio eradication \u2013 Worldwide, January 2018 \u2013 March 2020","volume":"69","author":"Chard","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2023.01.048_b0010","unstructured":"WHO. Polio Case Count. <https:\/\/extranet.who.int\/polis\/public\/CaseCount.aspx> [accessed December 7, 2022]."},{"key":"10.1016\/j.vaccine.2023.01.048_b0015","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1146\/annurev.micro.58.030603.123625","article-title":"Vaccine-derived polioviruses and the Endgame Strategy for Global Polio Eradication","volume":"59","author":"Kew","year":"2005","journal-title":"Ann Rev Microbiol"},{"issue":"35","key":"10.1016\/j.vaccine.2023.01.048_b0020","doi-asserted-by":"crossref","first-page":"934","DOI":"10.15585\/mmwr.mm6535a3","article-title":"Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine \u2013 worldwide, 2016","volume":"65","author":"Hampton","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2023.01.048_b0025","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/j.vaccine.2022.03.056","volume":"40","author":"Crothers","year":"2022","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2023.01.048_b0030","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/infdis\/jiaa393","article-title":"The long and winding road to eradicate vaccine-related polioviruses","volume":"223","author":"Cochi","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.01.048_b0035","unstructured":"World Health Organization. Market information for access to vaccines. Available via WHO.int. <https:\/\/www.who.int\/teams\/immunization-vaccines-and-biologicals\/vaccine-access\/mi4a\/mi4a> [accessed December, 2022]."},{"issue":"5","key":"10.1016\/j.vaccine.2023.01.048_b0040","doi-asserted-by":"crossref","DOI":"10.2217\/fmb.15.19","article-title":"Polio vaccination: past, present and future","volume":"10","author":"Bandyopadhyay","year":"2015","journal-title":"Fut Microbiol"},{"key":"10.1016\/j.vaccine.2023.01.048_b0045","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1016\/j.vaccine.2020.02.066","article-title":"Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, following vaccination in children at 2, 4, 6 and at 15\u201318 months","volume":"38","author":"S\u00e1ez-Llorens","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.01.048_b0050","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.vaccine.2019.10.064","article-title":"Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, compared to standard IPV: A phase 3 observer-blinded, randomised, controlled trial in infants vaccinated at 6, 10, 14 weeks and 9 months of age","volume":"38","author":"Bravo","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.01.048_b0055","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1016\/j.vaccine.2021.08.032","article-title":"Safety and immunogenicity of intramuscularly administered CS6 subunit vaccine with a modified heat-labile enterotoxin from enterotoxigenic Escherichia coli","volume":"39","author":"Lee","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.01.048_b0060","doi-asserted-by":"crossref","first-page":"e0224073","DOI":"10.1371\/journal.pone.0224073","article-title":"Evaluation of the reactogenicity, adjuvanticity and antigenicity of LT(R192G) and LT(R192G\/L211A) by intradermal immunization in mice","volume":"14","author":"Maciel","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2023.01.048_b0065","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.vaccine.2015.02.069","article-title":"The novel adjuvant dmLT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model","volume":"33","author":"Norton","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.01.048_b0070","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.4161\/hv.32253","article-title":"Serum and mucosal antibody responses to inactivated polio vaccine after sublingual immunization using a thermoresponsive gel delivery system","volume":"10","author":"White","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2023.01.048_b0075","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S1473-3099(19)30571-7","article-title":"Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants: a double-blind, randomised, placebo-controlled phase 1\/2 trial","volume":"20","author":"Qadri","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2023.01.048_b0080","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/nprot.2013.058","article-title":"Enzyme-linked immunospot assays for direct ex vivo measurement of vaccine-induced human humoral immune responses in blood","volume":"8","author":"Saletti","year":"2013","journal-title":"Nat Protoc"},{"key":"10.1016\/j.vaccine.2023.01.048_b0085","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0140-6736(19)31279-6","article-title":"The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double- blind, single-centre phase 1 study","volume":"394","author":"Van Damme","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.01.048_b0090","series-title":"Poliovirus: methods in molecular biology","first-page":"145","article-title":"Standardized methods for detection of poliovirus antibodies","author":"Weldon","year":"2016"},{"key":"10.1016\/j.vaccine.2023.01.048_b0095","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1128\/JCM.43.6.2886-2894.2005","article-title":"Genomic analysis of vaccine-derived poliovirus strains in stool specimens by combination of full-length PCR and oligonucleotide microarray hybridization","volume":"43","author":"Laassri","year":"2005","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2023.01.048_b0100","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1128\/CVI.05225-11","article-title":"Development of a poliovirus neutralization test with poliovirus pseudovirus for measurement of neutralizing antibody titer in human serum","volume":"18","author":"Arita","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2023.01.048_b0105","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/infdis\/jit671","article-title":"Intestinal immunity is a determinant of clearance of poliovirus after oral vaccination","volume":"209","author":"Wright","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.01.048_b0110","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/sim.4780091208","article-title":"Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk","volume":"9","author":"Farrington","year":"1990","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2023.01.048_b0115","first-page":"1","article-title":"The natural duration of cancer","author":"Greenwood","year":"1926","journal-title":"Rep Public Health Med Subj"},{"issue":"1","key":"10.1016\/j.vaccine.2023.01.048_b0120","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1084\/jem.96.1.99","article-title":"Transitory appearance of type 2 neutralizing antibody in patients infected with type 1 poliomyelitis virus","volume":"96","author":"Sabin","year":"1952","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2023.01.048_b0125","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1080\/21645515.2020.1812315","article-title":"Safety and immunogenicity of a new Sabin inactivated poliovirus vaccine candidate produced on the PER.C6\u00ae cell-line: a phase 1 randomized controlled trial in adults","volume":"17","author":"Leroux-Roels","year":"2021","journal-title":"Hum Vacc Immunother"},{"issue":"1","key":"10.1016\/j.vaccine.2023.01.048_b0130","doi-asserted-by":"crossref","first-page":"e0146010","DOI":"10.1371\/journal.pone.0146010","article-title":"Human circulating antibody-producing B cell as a predictive measure of mucosal immunity to poliovirus","volume":"11","author":"Dey","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2023.01.048_b0135","first-page":"jiaa783","article-title":"Intestinal antibody responses to two novel live attenuated type 2 oral poliovirus vaccines in healthy adults in Belgium","author":"Brickley","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.01.048_b0140","doi-asserted-by":"crossref","first-page":"6816","DOI":"10.1016\/j.vaccine.2015.09.039","article-title":"Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial","volume":"33","author":"Anand","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.01.048_b0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41385-021-00428-0","article-title":"Mucosal immunity to poliovirus","volume":"15","author":"Connor","year":"2021","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.vaccine.2023.01.048_b0150","unstructured":"Meeting of the Strategic Advisory Group of Experts on immunization, October 2017 \u2013 conclusions and recommendations. Wkly Epidemiol Rec 2017; 92: 729\u201348."},{"key":"10.1016\/j.vaccine.2023.01.048_b0155","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S1473-3099(19)30301-9","article-title":"Vaccine schedules and the effect on humoral and intestinal immunity against poliovirus: a systematic review and network meta-analysis","author":"Macklin","year":"2019","journal-title":"Lancet Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23000786?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23000786?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:23:18Z","timestamp":1759404198000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23000786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0264410X23000786"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.01.048","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, tolerability, and immunogenicity of inactivated poliovirus vaccine with or without E.coli double mutant heat-labile toxin (dmLT) adjuvant in healthy adults; a phase 1 randomized study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.01.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}